Michelle Rosenzwajg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/149487/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mast cells drive pathologic vascular lesions in Takayasu arteritis. Journal of Allergy and Clinical Immunology, 2022, 149, 292-301.e3.	1.5	7
2	Interferon signature in giant cell arteritis aortitis. Journal of Autoimmunity, 2022, 127, 102796.	3.0	14
3	Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial. Critical Care, 2022, 26, 48.	2.5	62
4	Parental autoimmune and autoinflammatory disorders as multiple risk factors for common neurodevelopmental disorders in offspring: a systematic review and meta-analysis. Translational Psychiatry, 2022, 12, 112.	2.4	12
5	Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. , 2022, 10, e004699.		29
6	Regulatory T cell/Th17 balance in the pathogenesis of paediatric Behçet disease. Rheumatology, 2021, 61, 422-429.	0.9	17
7	Fever during pregnancy as a risk factor for neurodevelopmental disorders: results from a systematic review and meta-analysis. Molecular Autism, 2021, 12, 60.	2.6	18
8	Regulatory T lymphocytes/Th17 lymphocytes imbalance in autism spectrum disorders: evidence from a meta-analysis. Molecular Autism, 2021, 12, 68.	2.6	17
9	T regulatory cells activation and distribution are modified in critically ill patients with acute respiratory distress syndrome: A prospective single-centre observational study. Anaesthesia, Critical Care & Pain Medicine, 2020, 39, 35-44.	0.6	16
10	<i>NCKAP1L</i> defects lead to a novel syndrome combining immunodeficiency, lymphoproliferation, and hyperinflammation. Journal of Experimental Medicine, 2020, 217, .	4.2	48
11	Response to: â€~Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors' by Meyer et al. Annals of the Rheumatic Diseases, 2020, 80, annrheumdis-2019-216598.	0.5	0
12	Neutrophil–Platelet and Monocyte–Platelet Aggregates in COVID-19 Patients. Thrombosis and Haemostasis, 2020, 120, 1733-1735.	1.8	41
13	Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities. Autoimmunity Reviews, 2020, 19, 102586.	2.5	80
14	Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a Phase I/II randomised, double-blind, placebo-controlled, dose-finding study. Diabetologia, 2020, 63, 1808-1821.	2.9	50
15	Targeting JAK/STAT pathway in Takayasu's arteritis. Annals of the Rheumatic Diseases, 2020, 79, 951-959.	0.5	56
16	Immunomodulatory role of Interleukin-33 in large vessel vasculitis. Scientific Reports, 2020, 10, 6405.	1.6	11
17	TLR9 signalling in HCV-associated atypical memory B cells triggers Th1 and rheumatoid factor autoantibody responses. Journal of Hepatology, 2019, 71, 908-919.	1.8	23
18	Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Annals of the Rheumatic Diseases, 2019, 78, 209-217.	0.5	273

2

#	Article	IF	CITATIONS
19	A standardized flow cytometry procedure for the monitoring of regulatory T cells in clinical trials. Cytometry Part B - Clinical Cytometry, 2018, 94, 777-782.	0.7	29
20	Clinical and multi-omics cross-phenotyping of patients with autoimmune and autoinflammatory diseases: the observational TRANSIMMUNOM protocol. BMJ Open, 2018, 8, e021037.	0.8	17
21	Deep phenotyping of immune cell populations by optimized and standardized flow cytometry analyses. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2018, 93, 793-802.	1.1	43
22	Pharmacodynamics of regulatory T cells in mice and humans treated with low-dose IL-2. Journal of Allergy and Clinical Immunology, 2018, 142, 1344-1346.e3.	1.5	10
23	IL-2 antibodies in type 1 diabetes and during IL-2 therapy. Diabetologia, 2018, 61, 2066-2068.	2.9	3
24	Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus–Induced Cryoglobulinemia Vasculitis. Gastroenterology, 2017, 152, 2052-2062.e2.	0.6	81
25	B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab. Kidney International, 2017, 92, 227-237.	2.6	102
26	Polyvalent immunoglobulins, platelet lysate and lenalidomide: cocktail for polyfunctional NK cells expansion for multiple myeloma. Bone Marrow Transplantation, 2017, 52, 480-483.	1.3	5
27	Narcolepsy Type 1 Is Associated with a Systemic Increase and Activation of Regulatory T Cells and with a Systemic Activation of Global T Cells. PLoS ONE, 2017, 12, e0169836.	1.1	36
28	A possible role for IL-17 in Clarkson's disease. European Journal of Paediatric Neurology, 2016, 20, 953-956.	0.7	7
29	Therapeutic Effects of Human Mesenchymal Stem Cell–derived Microvesicles in Severe Pneumonia in Mice. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 324-336.	2.5	392
30	Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients. Journal of Autoimmunity, 2015, 58, 48-58.	3.0	214
31	Th1 and Th17 Cytokines Drive Inflammation in Takayasu Arteritis. Arthritis and Rheumatology, 2015, 67, 1353-1360.	2.9	195
32	Selective IL-2 Responsiveness of Regulatory T Cells Through Multiple Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes. Diabetes, 2015, 64, 2172-2183.	0.3	170
33	Human and Mouse CD8+CD25+FOXP3+ Regulatory T Cells at Steady State and during Interleukin-2 Therapy. Frontiers in Immunology, 2015, 6, 171.	2.2	177
34	Th1 Response and Systemic Treg Deficiency in Inclusion Body Myositis. PLoS ONE, 2014, 9, e88788.	1.1	65
35	CD21 ^{â^'/low} Marginal Zone B Cells Highly Express Fc Receptor–like 5 Protein and Are Killed by Anti–Fc Receptor–like 5 Immunotoxins in Hepatitis C Virus–Associated Mixed Cryoglobulinemia Vasculitis. Arthritis and Rheumatology, 2014, 66, 433-443.	2.9	16
36	Serum biomarker signature identifies patients with B-cell non-Hodgkin lymphoma associated with cryoglobulinemia vasculitis in chronic HCV infection. Autoimmunity Reviews, 2014, 13, 319-326.	2.5	20

MICHELLE ROSENZWAJG

#	Article	IF	CITATIONS
37	Interleukin 2 in the Pathogenesis and Therapy of Type 1 Diabetes. Current Diabetes Reports, 2014, 14, 553.	1.7	28
38	Lymphodepletion followed by infusion of suicide gene-transduced donor lymphocytes to safely enhance their antitumor effect: a phase I/II study. Leukemia, 2014, 28, 2406-2410.	3.3	16
39	Interleukin-5–producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy. Blood, 2014, 124, 3572-3576.	0.6	100
40	Low-dose Interleukin-2 in the Treatment of Autoimmune Disease. Oncology & Hematology Review, 2014, 10, 157.	0.2	6
41	Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2013, 1, 295-305.	5.5	359
42	Phase I clinical trial combining imatinib mesylate and IL-2. Oncolmmunology, 2013, 2, e23080.	2.1	29
43	Expansion of Autoreactive Unresponsive CD21 ^{â^'/low} B Cells in Sjögren's Syndrome–Associated Lymphoproliferation. Arthritis and Rheumatism, 2013, 65, 1085-1096.	6.7	176
44	Lymphodepletion Followed By Suicide-Gene-Transduced Donor Lymphocyte Infusion: A Strategy To Safely Enhance The Graft-Versus-Tumor Effect. Blood, 2013, 122, 153-153.	0.6	0
45	Depletion of T regulatory cells through selection of CD127-positive cells results in a population enriched in memory T cells: implications for anti-tumor cell therapy. Haematologica, 2012, 97, 1678-1685.	1.7	13
46	Interleukin 21 Correlates with T Cell and B Cell Subset Alterations in Systemic Lupus Erythematosus. Journal of Rheumatology, 2012, 39, 1819-1828.	1.0	100
47	Restoration of regulatory and effector T cell balance and B cell homeostasis in systemic lupus erythematosus patients through vitamin D supplementation. Arthritis Research and Therapy, 2012, 14, R221.	1.6	156
48	Interleukinâ€21 modulates Th1 and Th17 responses in giant cell arteritis. Arthritis and Rheumatism, 2012, 64, 2001-2011.	6.7	147
49	Critical role of IL-21 in modulating TH17 and regulatory TÂcells in Behçet disease. Journal of Allergy and Clinical Immunology, 2011, 128, 655-664.	1.5	196
50	Regulatory T Cell Content in the Bone Marrow Graft Does Not Predict the Occurrence of Acute GVHD. Biology of Blood and Marrow Transplantation, 2011, 17, 265-269.	2.0	24
51	Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis. New England Journal of Medicine, 2011, 365, 2067-2077.	13.9	683
52	Expansion of Functionally Anergic CD21â^'/low Marginal Zone-like B Cell Clones in Hepatitis C Virus Infection-Related Autoimmunity. Journal of Immunology, 2011, 187, 6550-6563.	0.4	89
53	A Subset of Monocytic Cells Derived From Human Embryonic Stem Cells Can Give Rise to Mesenchymal Stromal Cells,. Blood, 2011, 118, 3416-3416.	0.6	0
54	Interleukin-25: a cytokine linking eosinophils and adaptive immunity in Churg-Strauss syndrome. Blood, 2010, 116, 4523-4531.	0.6	126

#	Article	IF	CITATIONS
55	Delayed recovery after autologous peripheral hematopoietic cell transplantation: potential effect of a high number of total nucleated cells in the graft. Transfusion, 2010, 50, 2649-2659.	0.8	26
56	CD4 ⁺ CD25 ⁺ Regulatory T Cell Depletion Improves the Graft-Versus-Tumor Effect of Donor Lymphocytes After Allogeneic Hematopoietic Stem Cell Transplantation. Science Translational Medicine, 2010, 2, 41ra52.	5.8	83
57	Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer. International Journal of Oncology, 2009, 35, 569-81.	1.4	41
58	The B lymphocyte stimulator receptor–ligand system in hepatitis C virus-induced B cell clonal disorders. Annals of the Rheumatic Diseases, 2009, 68, 337-344.	0.5	44
59	IL-10-secreting T cells from HIV-infected pregnant women downregulate HIV-1 replication: effect enhanced by antiretroviral treatment. Aids, 2009, 23, 9-18.	1.0	29
60	Clinical grade preparation of human natural regulatory T ells encoding the thymidine kinase suicide gene as a safety gene: authors' reponse. Journal of Gene Medicine, 2009, 11, 737-738.	1.4	1
61	Efficacy and tolerability of rituximab with or without PEGylated interferon alfaâ€2b plus ribavirin in severe hepatitis C virus–related vasculitis: A longâ€ŧerm followup study of thirtyâ€ŧwo patients. Arthritis and Rheumatism, 2009, 60, 2531-2540.	6.7	99
62	Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue. Gut, 2009, 58, 520-529.	6.1	228
63	Clinicalâ€grade preparation of human natural regulatory Tâ€cells encoding the thymidine kinase suicide gene as a safety gene. Journal of Gene Medicine, 2008, 10, 834-846.	1.4	19
64	Correlation of clinical and virologic responses to antiviral treatment and regulatory T cell evolution in patients with hepatitis C virus–induced mixed cryoglobulinemia vasculitis. Arthritis and Rheumatism, 2008, 58, 2897-2907.	6.7	37
65	Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis. Blood, 2008, 111, 5334-5341.	0.6	101
66	Small intestinal CD4+ T-cell lymphoma: a rare distinctive clinicopathological entity associated with prolonged survival. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 451, 1091-1093.	1.4	27
67	The BLyS/BAFF Receptor-Ligand System in HCV Induced B-Cell Clonal Disorders Blood, 2007, 110, 3866-3866.	0.6	1
68	Clinical and Virological Responses to Anti-Viral Treatment Correlates with Regulatory T-Cells Evolution in Patients with HCV-Induced Cryoglobulinemia Vasculitis Blood, 2007, 110, 3867-3867.	0.6	0
69	Ex Vivo Expansion Does Not Alter the Capacity of Umbilical Cord Blood CD34+Cells to Generate Functional T Lymphocytes and Dendritic Cells. Stem Cells, 2006, 24, 2150-2157.	1.4	16
70	Immediate-early antigen expression and modulation of apoptosis after in vitro infection of polymorphonuclear leukocytes by human cytomegalovirus. Microbes and Infection, 2005, 7, 1139-1149.	1.0	15
71	Cell Cycle Arrest in G 2 Induces Human Immunodeficiency Virus Type 1 Transcriptional Activation through Histone Acetylation and Recruitment of CBP, NF-ήB, and c-Jun to the Long Terminal Repeat Promoter. Journal of Virology, 2004, 78, 12198-12206.	1.5	49
72	Bcl-2 and Immunoglobulin Gene Rearrangements in Patients with Malaria Related Chronic Splenomegaly. Leukemia and Lymphoma, 2004, 45, 2093-2097.	0.6	3

MICHELLE ROSENZWAJG

#	Article	IF	CITATIONS
73	Incidence of Ex Vivo Expansion on the Capacity of Cord Blood Graft To Generate Immune Cells: Rational for Co-Infusion of Expanded and Non Expanded Fractions? Blood, 2004, 104, 407-407.	0.6	2
74	Double-stranded RNA stimulation or CD40 ligation of monocyte-derived dendritic cells as models to study their activation and maturation process. European Cytokine Network, 2004, 15, 126-34.	1.1	8
75	Constrained Intracellular Survival of <i>Mycobacterium tuberculosis</i> in Human Dendritic Cells. Journal of Immunology, 2003, 170, 1939-1948.	0.4	155
76	Highly active antiretroviral therapy corrects hematopoiesis in HIV-1 infected patients. Aids, 2003, 17, 563-574.	1.0	18
77	DENDRITIC CELLS: A COMPLEX SIMPLICITY. Transplantation, 2002, 73, S3-S6.	0.5	20
78	CD40 ligation and phagocytosis differently affect the differentiation of monocytes into dendritic cells. Journal of Leukocyte Biology, 2002, 72, 1180-9.	1.5	10
79	CD13/N-aminopeptidase is involved in the development of dendritic cells and macrophages from cord blood CD34+ cells. Blood, 2000, 95, 453-460.	0.6	45
80	Human herpes virus 8 (HHV8) serology in allogeneic bone marrow transplant recipients. Bone Marrow Transplantation, 1999, 24, 351-354.	1.3	34
81	Differentiation of human dendritic cells from monocytesin vitro. European Journal of Immunology, 1997, 27, 431-441.	1.6	311
82	Susceptibility of Human Bone Marrow Stromal Cells to Human Immunodeficiency Virus (HIV). Virology, 1995, 208, 779-783.	1.1	40